Is Boundless Bio, Inc. Common Stock a growth stock? A data-driven read on its earnings momentum, price leadership, and demand, scored against every US stock from SEC filings and daily prices, and re-ranked after every close.
Partly. BOLD is a mixed caseAs of the 2026-07-28 close, BOLD scores 59 out of 99 on our growth-stock rating, a mixed growth-stock profile. That ranks it 906th of 4,892 rated US stocks, the top 19% of the market.
Its strongest trait is I (institutional sponsorship) at 100, and its weakest is A (annual earnings growth) at 7. BOLD clears 3 of the six core growth traits we score per stock; the seventh, overall market direction, is judged market-wide.
On price, BOLD carries an elite Relative Strength rating of 95, meaning it has outperformed about 95% of the market over the past year.
Underneath the score: trading 5% below its 52-week high.
The six traits that separate real growth stocks from the rest: earnings, price leadership, and demand. Each is scored 1–99 against the whole US market. We compute them with the CANSLIM method, double-weighting earnings and relative strength.
| C | Current quarterly earnings most recent EPS growth vs. a year ago |
10 |
| A | Annual earnings growth multi-year earnings trend |
7 |
| N | New highs & catalysts proximity to new 52-week highs |
63 |
| S | Supply & demand volume behind the move vs. share supply |
38 |
| L | Leader or laggard Relative Strength within its group |
67 |
| I | Institutional sponsorship fund accumulation and 13F ownership |
100 |
BOLD passes some CANSLIM traits but not others. The letter breakdown above shows exactly where it holds up and where it falls short.
The stocks ranking above BOLD today, the growth leaders you’d weigh against it.
Where BOLD sits in its base, its 52-week path, and the trait trend over the past year.
Every US stock scored on the traits that define a growth stock and re-ranked after each close, with the top ranks, the full trait breakdown, and today’s market read.
Open the app, free through September 1Partly. BOLD is a mixed case. BOLD passes some CANSLIM traits but not others. The letter breakdown above shows exactly where it holds up and where it falls short.
Boundless Bio, Inc. Common Stock (BOLD) scores 59 out of 99 on our growth-stock rating as of the 2026-07-28 close, ranking 906th of 4,892 rated US stocks.
We don't have current earnings-growth figures for BOLD.
BOLD has a Relative Strength rating of 95, meaning it has outperformed roughly 95% of the US market over the trailing year.
Create a free Growth Stock Analyzer account to see where BOLD ranks against every US stock, the stronger growth stocks to weigh against it, and its full price and earnings history.
Want the method behind the score? Read how we grade growth stocks with CANSLIM.